Autologous-Conditioned Serum: Evidence for Use in the Knee

Abstract

Since the first description of autologous-conditioned serum (ACS) almost two decades ago, there has been a presumption of beneficial proteins found within this product. Thought to be a key protein in ACS, interleukin 1 receptor antagonist (IL-1Ra) has received the majority of the attention; although the extent of biological proteins is not known and likely because of the autologous nature of the product, vary from individual to individual. Following the positive anecdotal evidence, preclinical data demonstrated both symptom and disease-modifying effects. These results were followed by two randomized placebo-controlled clinical trials, both showing significant improvement compared with placebo or hyaluronan acid in one study for quality of life, pain, and patient assessed efficacy when ACS was administered in the human knee. Much is still unknown regarding the key active proteins found in ACS as well as definitive dosing, frequency, and administration time postinjury, which hopefully will be the focus of future studies.

Keywords

autologous-conditioned serum - knee - joint - IRAP - therapy

• References

• 1 Chevalier X, Giraudeau B, Conrozier T, Marliere J, Kiefer P, Goupille P. Safety study of intraarticular injection of interleukin 1 receptor antagonist in patients with painful knee osteoarthritis: a multicenter study. J Rheumatol 2005; 32 (7) 1317-1323
• 2 Chevalier X, Goupille P, Beaulieu AD , et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009; 61 (3) 344-352
• 3 Food and Drug Administration. Kineret (anakinra) (Recombinant methionyl human interleukin-1 receptor antagonist) Arthritis Drug Advisor Committee Briefing Package; July 17, 2001 ; Thousand Oaks, CA. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3779b1_01_Amgen.pdf
• 4 Kraus VB, Birmingham J, Stabler TV , et al. Effects of intraarticular IL1-Ra for acute anterior cruciate ligament knee injury: a randomized controlled pilot trial (NCT00332254). Osteoarthritis Cartilage 2012; 20 (4) 271-278
• 5 Mitroulis I, Skendros P, Ritis K. Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome. Eur J Intern Med 2010; 21 (3) 157-163
• 6 Evans CH, Gouze JN, Gouze E, Robbins PD, Ghivizzani SC. Osteoarthritis gene therapy. Gene Ther 2004; 11 (4) 379-389
• 7 Evans CH, Robbins PD, Ghivizzani SC , et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci U S A 2005; 102 (24) 8698-8703
• 8 Meijer H, Reinecke J, Becker C, Tholen G, Wehling P. The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. Inflamm Res 2003; 52 (10) 404-407
• 9 Hannum CH, Wilcox CJ, Arend WP , et al. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343 (6256) 336-340
• 10 Carter DB, Deibel Jr MR, Dunn CJ , et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990; 344 (6267) 633-638
• 11 Wehling P, Moser C, Frisbie D , et al. Autologous conditioned serum in the treatment of orthopedic diseases: the orthokine therapy. BioDrugs 2007; 21 (5) 323-332
• 12 Frisbie DD, Kawcak CE, Werpy NM, Park RD, McIlwraith CW. Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. Am J Vet Res 2007; 68 (3) 290-296
• 13 Ferris DJ, Frisbie DD, McIlwraith CW, Kawcak CE. Current joint therapy usage in equine practice: a survey of veterinarians 2009. Equine Vet J 2011; 43 (5) 530-535
• 14 Baltzer AWA, Drever R, Granrath M, Godde G, Klein W, Wehling P. Intraarticular treatment of osteoarthritis using autologous interleukin-1 receptor antagonist (IL-1Ra) conditioned serum. Dtsch Z Sportmed 2003; 54 (6) 209-211
• 15 Baltzer AW, Moser C, Jansen SA, Krauspe R. Autologous conditioned serum (Orthokine) is an effective treatment for knee osteoarthritis. Osteoarthritis Cartilage 2009; 17 (2) 152-160
• 16 Darabos N, Haspl M, Moser C, Darabos A, Bartolek D, Groenemeyer D. Intraarticular application of autologous conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial. Knee Surg Sports Traumatol Arthrosc 2011; 19 (Suppl. 01) S36-S46